MedTrace Logo

British Axial Spondyloarthritis Inception Cohort

NCT05676775 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-07-18

No results posted yet for this study

Summary

The British Axial Spondyloarthritis Cohort (BAxSIC) study has been established under the auspices of the British Society for Spondyloarthritis (BRITSpA) in collaboration with the National Axial Spondyloarthritis Society (NASS) to provide real-world data to evaluate the impact of delay in diagnosis (from symptom onset to diagnosis) on work participation and functional outcomes and the natural history and impact of newly-diagnosed axial Spondyloarthritis, including disease activity, pain, fatigue, functional and work outcomes, comorbidities, therapies in the United Kingdom (UK). The study is a prospective cohort, enrolling patients attending rheumatology clinics in the UK who are newly diagnosed with axial Spondyloarthritis and naïve to biologic therapy.

The study will run for an initial 3 year period commencing January 2023. Financial support was provided as a Research Grant from Pfizer Limited, UCB and Novartis.

Conditions

  • Axial Spondyloarthritis

Interventions

OTHER

No intervenetion

Observational inception cohort, with remote follow-up via participants and data record linkage

Sponsors & Collaborators

  • The Leeds Teaching Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Helena Marzo-Ortega, MD/PhD · Leeds Teaching Hospital Trust

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-09
Primary Completion
2026-01-09
Completion
2029-01-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05676775 on ClinicalTrials.gov